Primary Tauopathies
Understanding the Causes of Neurodegeneration to Advance New Treatments
Primary tauopathies are a group of progressive neurodegenerative diseases characterized by the abnormal accumulation of tau protein in the brain. These disorders include frontotemporal dementia caused by tau pathology (FTD-tau), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). They can profoundly affect memory, behavior, movement, and the ability to perform everyday activities.
At the Neural Stem Cell Institute (NSCI), our scientists are using human stem cell technology, advanced brain organoid models, and molecular analysis to understand how tau-related diseases develop and identify new opportunities for therapeutic intervention.
Our goal is to uncover the earliest changes that lead to neurodegeneration—before irreversible damage occurs.
Understanding Primary Tauopathies
Tau is a protein that normally helps maintain the structure and function of neurons. In tauopathies, tau becomes abnormal, disrupting cellular processes and contributing to the progressive loss of brain cells.
Although these disorders share tau pathology, they affect different brain regions and produce distinct clinical symptoms. There are currently no approved treatments that stop or reverse the underlying neurodegeneration in primary tauopathies.
Understanding why certain neurons become vulnerable, how tau pathology develops, and which cellular pathways are disrupted is essential to developing more effective treatments.
Modeling Human Brain Disease with Stem Cells
Studying neurodegeneration in human brain tissue—without waiting for advanced disease.
One of the greatest challenges in studying tauopathies is understanding what happens in the brain years before symptoms appear.
NSCI researchers use human induced pluripotent stem cells (iPSCs) to generate three-dimensional brain organoids—miniature, laboratory-grown models containing neurons and supporting cells that reproduce important features of human brain development.
By creating organoids from stem cells carrying disease-associated mutations in the MAPT gene, which encodes tau, researchers can investigate how genetic changes affect brain cells over time.
These models allow our scientists to:
- Identify early molecular changes that precede neuronal degeneration.
- Investigate how abnormal tau affects neurons and supporting glial cells.
- Understand why specific populations of neurons are especially vulnerable.
- Compare disease-associated mutations with genetically matched controls.
- Identify potential therapeutic targets and evaluate experimental interventions.
This approach provides an important bridge between fundamental discoveries and the development of new treatments for neurodegenerative diseases.
Our Research Discoveries
Revealing Early Changes Before Neurons Die
In a landmark study published in Cell (2021), NSCI scientists and collaborators used human cerebral organoids carrying the tau V337M mutation to investigate the progression of frontotemporal dementia.
The study identified changes in RNA processing, glutamate signaling, and cellular stress that emerged before significant neuronal loss. These findings helped establish that the biological processes leading to neurodegeneration begin well before neurons die.
Importantly, the researchers demonstrated that a pharmacological intervention could protect vulnerable neurons from glutamate-related toxicity in the experimental model, highlighting a potential direction for therapeutic development.
Identifying Disrupted Cholesterol Regulation
A subsequent study published in Stem Cell Reports (2022) revealed an unexpected connection between tau mutations and cholesterol metabolism.
Using cerebral organoids carrying disease-associated MAPT mutations, researchers discovered increased activity of cholesterol biosynthesis pathways in astrocytes—supporting cells that play essential roles in maintaining brain health.
These findings suggest that disturbances in cholesterol regulation may contribute to the earliest stages of tau-related neurodegeneration and offer new avenues for investigating disease mechanisms.
Advancing the Quality and Reliability of Human Disease Models
In research published in Neuron (2026), NSCI and collaborators conducted comprehensive molecular profiling of 85 human iPSC lines carrying MAPT mutations and genetically matched controls.
The study identified important sources of cellular and genomic variation that can influence organoid development and the interpretation of disease-related findings.
By improving the characterization of stem cell lines, this research provides a stronger foundation for reliable, reproducible studies of tauopathies and other neurological disorders.
Building Scalable, Reproducible Brain Organoid Platforms
In a 2026 study published by Nature, NSCI researchers and collaborators developed an integrated platform for manufacturing and evaluating human cortical organoids.
Using multiple MAPT mutation models, the team established a scalable approach with comprehensive quality-control measures designed to improve organoid consistency and biological relevance.
The study identified early changes in proteins involved in cellular regulation and protein folding in neurons carrying the tau V337M mutation, before the appearance of later tau-related abnormalities.
These advances make it possible to study early disease mechanisms more systematically and support the development of reproducible human models for future therapeutic research.
From Scientific Discovery to Therapeutic Development
NSCI’s primary tauopathy research brings together expertise in stem cell biology, neuroscience, genomics, and human disease modeling.
By combining patient-derived stem cells, genetically defined disease models, single-cell molecular analysis, and reproducible brain organoid production, our scientists are building the tools needed to better understand the origins of neurodegenerative disease.
These approaches can help identify new therapeutic targets, evaluate potential interventions, and improve the reliability of preclinical research.
Understanding how neurodegeneration begins is a critical step toward learning how to prevent it.
Collaboration and Research Resources
Scientific progress depends on collaboration.
NSCI works with academic and research partners to investigate the molecular mechanisms of tauopathies and advance human stem cell-based disease models.
Through our NeuraCell program, NSCI also develops human stem cell-derived neural organoids and related research resources to support neuroscience research and therapeutic discovery.
We welcome opportunities to collaborate with academic investigators, biotechnology companies, pharmaceutical researchers, and organizations committed to advancing treatments for neurodegenerative diseases.
Explore NeuraCell Research Models
Contact NSCI About Research Collaborations
Support Research That Could Change Lives
Primary tauopathies are devastating disorders for patients and families, and effective disease-modifying treatments remain an urgent unmet medical need.
Your support helps NSCI investigate the earliest causes of neurodegeneration, develop innovative human disease models, and advance research toward future treatments.
Together, we can accelerate discoveries that bring new hope to individuals and families affected by neurodegenerative disease.
